Madrigal Pharmaceuticals
Update in progressMDGL (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. Its lead product, Rezdiffra, is a liver-targeted thyroid hormone receptor beta agonist designed to treat MASH. Founded in 2016, the company is headquartered in West Conshohocken, Pennsylvania.
Company score
- Sentiment
- 0.76
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.08
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.52
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.21
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.48
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. William J. Sibold
- Founded2016
- Employees915
- Websitewww.madrigalpharma.com
Identifiers
- ISINUS5588681057
- FIGIBBG000QS6NV8
- LEI549300CHIMT2EUSNJB60
- CUSIP558868105
- CIK0001157601